Lantern Pharma to host live demonstration of withZeta.ai

Lantern Pharma (LTRN) will host an investor, analyst and shareholder briefing on Thursday, April 9, 2026 at 8:30 AM Eastern featuring a live demonstration of withZeta.ai – the world’s first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, and clinical trial design. The briefing will be conducted via live webcast and will cover the platform’s capabilities and commercial architecture, the rare cancer market opportunity, competitive positioning, and the Company’s near-term revenue strategy and growth roadmap. The investor and analyst briefing will be hosted by Panna Sharma, President and Chief Executive Officer and Kishor Bhatia, Ph.D., FRCP, Chief Scientific Officer of Lantern Pharma, and will cover the following: 1. The rare cancer imperative – why millions of patients across hundreds of distinct cancer types remain systemically underserved and why AI co-scientists are part of the solution 2. Live demonstration of withZeta.ai – the world’s first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, and clinical trial design 3. Platform capabilities and what makes withZeta.ai fundamentally different and an economic imperative in drug discovery and development. 4. Commercial subscription model, revenue strategy, and market opportunity 5. Competitive position in the AI drug discovery landscape 6. Strategic roadmap and upcoming milestones for withZeta.ai.